Saturday, February 16, 2019

Closing the Knowledge Gap to Improve Lung Cancer Treatment

Lung cancer is the leading cause of cancer death worldwide. The deadliness of the disease can be partially attributed to the late onset of symptoms, often resulting in late diagnosis. In fact, 70 percent of lung cancer cases are discovered in advanced stages. Despite growing awareness among physicians about the value of screening to identify lung cancer earlier, there are...

San Antonio Breast Cancer Symposium – Shifting Paradigms in Targeted Therapies

This year’s San Antonio Breast Cancer Symposium (SABCS) is taking place on December 5-9th, 2017, and it is expected to bring in a broad international audience of researchers and physicians to discuss the future of breast cancer research and treatment. SABCS is designed to provide state-of-the-art information on a range of topics, including the experimental biology, etiology, prevention, diagnosis, and...

ASH 2017: Expect an Invaluable Educational Experience

This year - from December 9 - 12, Oncologists and Hematologists will gather again in Atlanta, GA, the South's largest and most vibrant city, for the 59th annual meeting and exposition of the American Society of Hematology. This year, the organizers have developed an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the...

Charitable Efforts Know No Boundaries When Helping the Underserved— Stakeholders Strive to Continue Access to Breast Cancer Treatment in Arizona

When a steady, relied-upon source of funding was ending, a public-private coalition of concerned stakeholders was created in Arizona to ensure that certain critical health care services could be continued. In June, Susan G. Komen’s Arizona affiliate announced via a letter posted online that “based on financial challenges and current downward trends in overall fundraising and event participation which limited...

It’s Just the Beginning, but Much More Work Remains

Yesterday’s U.S. Food and Drug Administration’s (FDA) approval of the immunotherapy drug, CTL019 (tisagenlecleucel-T | Kymriah®; Novartis), for treatment of childhood Acute Lymphoblastic Leukemia (ALL), was a milestone in medicine, good news for patients, and a promising precursor for those involved in developing novel anticancer drugs. Although the approved use of the chimeric antigen receptor or CAR-T,--for advanced leukemia in...

Uniting in the War on Cancer

Current events have a way of bringing topics to the forefront of our consciousness. Matters previously receiving little attention from small groups are often thrust into the headlines and become widely discussed by pundits, experts, bloggers, and the general public. Such was the case, last week, when John McCain, the senior Senator from Arizona, and internationally recognized war hero who spent...

When a Child Dies – What Not To say to Bereaved Parents

Joan Markwell knows the gut-wrenching, hollow feeling left behind when a child is taken too early. It’s a feeling that mothers have experienced recently and throughout the last few years after tragic attacks in Orlando, Manchester, London, San Bernardino, Calif., and Charleston, S.C., just to name a few. With every new tragedy, vigil, story on the news or anniversary recognizing...

Eric Rosenthal Reports: Placing Cancer Fear in its Proper Perspective

During his first inaugural address in 1933, President Franklin D. Roosevelt famously said, “the only thing we have to fear is fear itself.” It was in the midst of the economic Depression and the newly elected president was trying to raise the hopes of a nation in despair suffering also from the throes of psychological depression. Earlier this month while attending...

How to Prevent Cancer: What Governments can do

By: Kelly Henning While much work remains to find a cure for cancer – the good news is we know that many forms of cancer are preventable. On World Cancer Day, a moment when the global community comes together to reflect on those lost to cancer, as well as the advances we need to make to find a cure, it’s...

Phase III Trial Finds that Anti-interleukin-1 alpha antibody MABp1

A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data presented at the European Society for Medical Oncology’s 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. Xilonix™ (XBiotech) is the first monoclonal antibody immunotherapy to specifically target...

right side

ads

Related articles